FDA's New Digital Health Unit and Guidance for MHealth and Telemedicine Companies
June 26, 2017
In connection with its efforts to support technological innovation and advancement of digital health, the U.S. Food and Drug Administration (FDA) has announced two new resources: 1) the creation of a new centralized Digital Health Unit within its Center for Devices and Radiological Health (CDRH) and 2) the issuance of draft guidance on Software as a Medical Device (SaMD): Clinical Evaluation released last fall.
SaMD is an area of digital health where FDA guidance has been rapidly evolving.
To continue reading this article written by Nathaniel Lacktman, Jason Drori and Taylor Whitten, click here.
SaMD is an area of digital health where FDA guidance has been rapidly evolving.
To continue reading this article written by Nathaniel Lacktman, Jason Drori and Taylor Whitten, click here.
Author(s)
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.